<?xml version='1.0' encoding='utf-8'?>
<document id="28066243"><sentence text="Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect."><entity charOffset="0-11" id="DDI-PubMed.28066243.s1.e0" text="Rivaroxaban" /></sentence><sentence text="We report a patient who presented a non-ST segment elevation myocardial infarction in the context of severe normocytic hypochromic anemia related to gastrointestinal bleeding, 3 months after switching anticoagulant from the vitamin K antagonist acenocoumarol to the direct oral anticoagulant rivaroxaban"><entity charOffset="224-233" id="DDI-PubMed.28066243.s2.e0" text="vitamin K" /><entity charOffset="245-258" id="DDI-PubMed.28066243.s2.e1" text="acenocoumarol" /><entity charOffset="292-303" id="DDI-PubMed.28066243.s2.e2" text="rivaroxaban" /><pair ddi="false" e1="DDI-PubMed.28066243.s2.e0" e2="DDI-PubMed.28066243.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28066243.s2.e0" e2="DDI-PubMed.28066243.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28066243.s2.e0" e2="DDI-PubMed.28066243.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28066243.s2.e1" e2="DDI-PubMed.28066243.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28066243.s2.e1" e2="DDI-PubMed.28066243.s2.e2" /></sentence><sentence text=" High levels of both anti-Xa activity and rivaroxaban plasma concentrations were measured despite rivaroxaban withdrawal, suggesting reduced elimination/drug clearance"><entity charOffset="42-53" id="DDI-PubMed.28066243.s3.e0" text="rivaroxaban" /><entity charOffset="98-109" id="DDI-PubMed.28066243.s3.e1" text="rivaroxaban" /><pair ddi="false" e1="DDI-PubMed.28066243.s3.e0" e2="DDI-PubMed.28066243.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28066243.s3.e0" e2="DDI-PubMed.28066243.s3.e1" /></sentence><sentence text=" Estimated half-life was 2-3 times longer than usually reported" /><sentence text=" The patient is a homozygous carrier of ABCB1 variant alleles, which could have participated to reduced elimination of rivaroxaban"><entity charOffset="119-130" id="DDI-PubMed.28066243.s5.e0" text="rivaroxaban" /></sentence><sentence text=" Furthermore, CYP3A4/5 phenotyping showed moderately reduced enzyme activity" /><sentence text=" Drug-drug interaction with simvastatin may have contributed to decreased rivaroxaban elimination"><entity charOffset="28-39" id="DDI-PubMed.28066243.s7.e0" text="simvastatin" /><entity charOffset="74-85" id="DDI-PubMed.28066243.s7.e1" text="rivaroxaban" /><pair ddi="false" e1="DDI-PubMed.28066243.s7.e0" e2="DDI-PubMed.28066243.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28066243.s7.e0" e2="DDI-PubMed.28066243.s7.e1" /></sentence><sentence text=" Although in the present case moderate acute renal failure probably played a role, more clinical data are required to elucidate the impact of ABCB1 polymorphism on rivaroxaban pharmacokinetics and bleeding complications"><entity charOffset="164-175" id="DDI-PubMed.28066243.s8.e0" text="rivaroxaban" /></sentence><sentence text="" /></document>